Sensus Healthcare, Inc. Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2026-08-14: Disclosure Material Terms Of Trading Arrangement; Period 2026-01-01..2026-06-30; Value During the three months ended June 30, 2026, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditio….
- 2026-08-14: Disclosure Non Rule10b51Arr Terminated; Period 2026-01-01..2026-06-30; Value No.
- 2026-08-14: Disclosure Rule10b51Arr Terminated; Period 2026-01-01..2026-06-30; Value No.
- 2026-08-14: Disclosure Non Rule10b51Arr Adopted; Period 2026-01-01..2026-06-30; Value No.
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2026-08-14 10-Q | Material Terms Of Trading Arrangement | 2026-01-01..2026-06-30 | During the three months ended June 30, 2026, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditio… | |
| 2026-08-14 10-Q | Non Rule10b51Arr Terminated | 2026-01-01..2026-06-30 | No | |
| 2026-08-14 10-Q | Rule10b51Arr Terminated | 2026-01-01..2026-06-30 | No | |
| 2026-08-14 10-Q | Non Rule10b51Arr Adopted | 2026-01-01..2026-06-30 | No | |
| 2026-08-14 10-Q | Rule10b51Arr Adopted | 2026-01-01..2026-06-30 | No | |
| 2026-05-13 10-Q | Material Terms Of Trading Arrangement | 2026-01-01..2026-03-31 | During the three months ended March 31, 2026, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditi… | |
| 2026-05-13 10-Q | Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-13 10-Q | Non Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-13 10-Q | Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-05-13 10-Q | Non Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-03-04 10-K | Rule10b51Arr Adopted | 2025-01-01..2025-12-31 | No | |
| 2026-03-04 10-K | Non Rule10b51Arr Adopted | 2025-01-01..2025-12-31 | No | |
| 2026-03-04 10-K | Rule10b51Arr Terminated | 2025-01-01..2025-12-31 | No | |
| 2026-03-04 10-K | Non Rule10b51Arr Terminated | 2025-01-01..2025-12-31 | No | |
| 2026-03-04 10-K | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes | |
| 2025-11-12 10-Q | Non Rule10b51Arr Terminated | 2025-07-01..2025-09-30 | No | |
| 2025-11-12 10-Q | Rule10b51Arr Terminated | 2025-07-01..2025-09-30 | No | |
| 2025-11-12 10-Q | Non Rule10b51Arr Adopted | 2025-07-01..2025-09-30 | No | |
| 2025-11-12 10-Q | Rule10b51Arr Adopted | 2025-07-01..2025-09-30 | No | |
| 2025-08-12 10-Q | Rule10b51Arr Adopted | 2025-01-01..2025-06-30 | No | |
| 2025-08-12 10-Q | Non Rule10b51Arr Adopted | 2025-01-01..2025-06-30 | No | |
| 2025-08-12 10-Q | Rule10b51Arr Terminated | 2025-01-01..2025-06-30 | No | |
| 2025-08-12 10-Q | Non Rule10b51Arr Terminated | 2025-01-01..2025-06-30 | No | |
| 2025-05-15 10-Q | Rule10b51Arr Adopted | 2025-01-01..2025-03-31 | No | |
| 2025-05-15 10-Q | Non Rule10b51Arr Adopted | 2025-01-01..2025-03-31 | No | |
| 2025-05-15 10-Q | Rule10b51Arr Terminated | 2025-01-01..2025-03-31 | No | |
| 2025-05-15 10-Q | Non Rule10b51Arr Terminated | 2025-01-01..2025-03-31 | No | |
| 2025-04-29 DEF 14A | Err Compensation Analysis | RestatementDate: 2023-10-02 | 2024-01-01..2024-12-31 | Effective October 2, 2023 , the Board of Directors updated our compensation recovery policy in accordance with the requirements of the Nasdaq listing standard adopted pursuant to SEC rules (the “Clawback Policy”). The Clawback Policy provides, among other things, that we will seek to recover any err… |
| 2025-04-29 DEF 14A | Restatement Determination Date | RestatementDate: 2023-10-02 | 2024-01-01..2024-12-31 | 2023-10-02 |
| 2025-04-29 DEF 14A | Insider Trading Policies Proc Adopted | 2024-01-01..2024-12-31 | Yes | |
| 2025-04-29 DEF 14A | Award Timing MNPI Disclosure | 2024-01-01..2024-12-31 | In the year ended December 31, 2024, we did not grant any stock options, stock appreciation rights, or similar awards. We do not currently plan to grant any such awards in the future. Accordingly, we do not have a policy or practice related to the timing or the determination of the terms of grants o… | |
| 2025-04-29 DEF 14A | MNPI Disclosure Timed For Compensation Val | 2024-01-01..2024-12-31 | No | |
| 2025-04-29 DEF 14A | Pay versus Performance Table | 2024-01-01..2024-12-31 | Pay Versus Performance Pay Versus Performance Table for 2024, 2023, and 2022 As required by the SEC rules, we are providing the following information regarding the relationship between executive compensation and our financial performance for each of the last three years. In determining “compensation… | |
| 2025-04-29 DEF 14A | Named Executive Officers Footnote | 2024-01-01..2024-12-31 | (1) The PEO in all three years is our CEO, Mr. J Sardano . (2) The non-PEO NEOs were Mr. M. Sardano and Mr. Rampolla. | |
| 2025-04-29 DEF 14A | Adjustment To Non PEO NEO Compensation Footnote | 2024-01-01..2024-12-31 | Adjustments to Determine Compensation “Actually Paid” for Non-PEO NEOs 2024 2023 2022 Deduction for Amounts Reported under the “Stock Awards” Column in the SCT — — — Increase for Fair Value of Awards Granted during year that Remain Unvested as of Year end — — — Increase for Fair Value of Awards Gran… | |
| 2025-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTbl; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | $0.00 |
| 2025-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTbl; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | $0.00 |
| 2025-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTbl; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | $0.00 |
| 2025-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | $0.00 |
| 2025-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | $0.00 |
| 2025-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | $0.00 |
| 2025-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | $0.00 |
| 2025-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | $0.00 |
| 2025-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | $0.00 |
| 2025-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | $0.00 |
| 2025-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | -$113.85K |
| 2025-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | $9.00K |
| 2025-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | $0.00 |
| 2025-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | $0.00 |
| 2025-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | $74.03K |
| 2025-04-29 DEF 14A | Adjustment To Compensation | ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | $0.00 |
| 2025-04-29 DEF 14A | Adjustment To Compensation | ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | -$113.85K |
| 2025-04-29 DEF 14A | Adjustment To Compensation | ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | $83.03K |
| 2025-04-29 DEF 14A | Compensation Actually Paid Vs Net Income | 2024-01-01..2024-12-31 | The graph below reflects the relationship between PEO and Average Non-PEO NEO CAP amounts and the Company’s TSR (assuming an initial investment of $100 made on December 31, 2021) for the fiscal years ending December 31, 2022, 2023, and 2024. | |
| 2025-04-29 DEF 14A | Compensation Actually Paid Vs Total Shareholder Return | 2024-01-01..2024-12-31 | The graph below reflects the relationship between PEO and Average Non-PEO NEO CAP amounts and the Company’s net income for the fiscal years ending December 31, 2022, 2023, and 2024. | |
| 2025-03-05 10-K | Insider Trading Policies Proc Adopted | 2024-01-01..2024-12-31 | Yes | |
| 2024-11-14 10-Q | Non Rule10b51Arr Adopted | 2024-07-01..2024-09-30 | No | |
| 2024-11-14 10-Q | Rule10b51Arr Adopted | 2024-07-01..2024-09-30 | No | |
| 2024-11-14 10-Q | Non Rule10b51Arr Terminated | 2024-07-01..2024-09-30 | No | |
| 2024-11-14 10-Q | Rule10b51Arr Terminated | 2024-07-01..2024-09-30 | No | |
| 2024-08-13 10-Q | Non Rule10b51Arr Adopted | 2024-04-01..2024-06-30 | No | |
| 2024-08-13 10-Q | Rule10b51Arr Adopted | 2024-04-01..2024-06-30 | No | |
| 2024-08-13 10-Q | Non Rule10b51Arr Terminated | 2024-04-01..2024-06-30 | No | |
| 2024-08-13 10-Q | Rule10b51Arr Terminated | 2024-04-01..2024-06-30 | No | |
| 2024-05-10 10-Q | Non Rule10b51Arr Adopted | 2024-01-01..2024-03-31 | No | |
| 2024-05-10 10-Q | Rule10b51Arr Adopted | 2024-01-01..2024-03-31 | No | |
| 2024-05-10 10-Q | Non Rule10b51Arr Terminated | 2024-01-01..2024-03-31 | No | |
| 2024-05-10 10-Q | Rule10b51Arr Terminated | 2024-01-01..2024-03-31 | No | |
| 2024-03-15 10-K | Non Rule10b51Arr Adopted | 2023-01-01..2023-12-31 | No | |
| 2024-03-15 10-K | Non Rule10b51Arr Terminated | 2023-01-01..2023-12-31 | No | |
| 2024-03-15 10-K | Rule10b51Arr Terminated | 2023-01-01..2023-12-31 | No | |
| 2024-03-15 10-K | Rule10b51Arr Adopted | 2023-01-01..2023-12-31 | No |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEPHROS INC (NEPH) | United States | $0.046B | 23.02 |
| Spectral AI, Inc. (MDAI) | United States | $0.052B | |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| SANUWAVE Health, Inc. (SNWV) | United States | $0.041B | 5.47 |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| InspireMD, Inc. (NSPR) | $0.033B | ||
| PAVmed Inc. (PAVM) | United States | $0.031B | -3.00 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| Glucotrack, Inc. (GCTK) | United States | $0.027B |